Objective: To study the clinical value of serum neuroglobin in evaluating hypoglycemic brain injury in neonates.
Methods: A total of 100 neonates with hypoglycemia were enrolled as subjects. According to amplitude-integrated EEG (aEEG) findings and/or clinical manifestations, they were divided into symptomatic hypoglycemic brain injury group (n=22), asymptomatic hypoglycemic brain injury group (n=37) and hypoglycemic non-brain injury group (n=41). The three groups were compared in terms of blood glucose, duration of hypoglycemia, levels of neuroglobin and neuron-specific enolase (NSE), and modified aEEG score. The correlation of neuroglobin with NSE and modified aEEG score was analyzed. The receiver operating characteristic (ROC) curve was plotted.
Results: Compared with the asymptomatic hypoglycemic brain injury and hypoglycemic non-brain injury groups, the symptomatic hypoglycemic brain injury group had significantly lower blood glucose and modified aEEG score, significantly higher neuroglobin and NSE levels, and a significantly longer duration of hypoglycemia (P<0.05). Compared with the hypoglycemic non-brain injury group, the asymptomatic hypoglycemic brain injury group had significantly lower blood glucose and modified aEEG score, significantly higher neuroglobin and NSE levels, and a significantly longer duration of hypoglycemia (P<0.05). Neuroglobin was positively correlated with NSE and duration of hypoglycemia (r=0.922 and 0.929 respectively; P<0.05) and negatively correlated with blood glucose and modified aEEG score (r=-0.849 and -0.968 respectively; P<0.05). The areas under the ROC curve of neuroglobin, NSE and modified aEEG score were 0.894, 0.890 and 0.941 respectively, and neuroglobin had a sensitivity of 80.8% and a specificity of 95.8% at the optimal cut-off value of 108 mg/L.
Conclusions: Like NSE and modified aEEG score, serum neuroglobin can also be used as a specific indicator for the assessment of brain injury in neonates with hypoglycemia and has a certain value in clinical practice.
目的: 探讨血清脑红蛋白（NGB）在新生儿低血糖脑损伤评估中的临床应用价值。
方法: 选择100例低血糖新生儿为研究对象。根据振幅整合脑电图（aEEG）结果和/或临床表现，分为3组：症状性低血糖脑损伤组（n=22）、无症状性低血糖脑损伤组（n=37）和低血糖无脑损伤组（n=41）。比较各组患儿血糖、低血糖持续时间、NGB及神经元特异性烯醇化酶（NSE）水平、改良aEEG评分；分析NGB与NSE水平、改良aEEG评分之间的相关性并绘制受试者工作特征（ROC）曲线等。
结果: 症状性低血糖脑损伤组血糖、改良aEEG评分低于无症状性低血糖脑损伤组及低血糖无脑损伤组（P < 0.05），NGB、NSE、低血糖持续时间高/长于无症状性低血糖脑损伤组及低血糖无脑损伤组（P < 0.05）。无症状低血糖脑损伤组血糖、改良aEEG评分低于低血糖无脑损伤组（P < 0.05），NGB、NSE及低血糖持续时间高/长于低血糖无脑损伤组（P < 0.05）。NGB与NSE、低血糖持续时间呈正相关（分别r=0.922、0.929，P < 0.05），与血糖、改良aEEG评分呈负相关（分别r=-0.849、-0.968，P < 0.05）；NGB、NSE、改良aEEG评分的ROC曲线下面积分别为0.894、0.890、0.941，NGB最佳截断值为108 mg/L，敏感度80.8%，特异度95.8%。
结论: 血清NGB与NSE、改良aEEG评分比较，同样可作为评估低血糖新生儿脑损伤的特异性指标，具有一定的临床应用价值。